Molecular Mechanisms of ARD1 in Tumors

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-03-03 DOI:10.1002/cam4.70708

Chunjiao Yu, Hongtao Lei, Xuefei Hou, Shan Yan

{"title":"Molecular Mechanisms of ARD1 in Tumors","authors":"Chunjiao Yu, Hongtao Lei, Xuefei Hou, Shan Yan","doi":"10.1002/cam4.70708","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Arrest-deficient protein 1 (ARD1) is an acetyltransferase that acetylates the N-terminal amino acids and internal lysine residues of proteins. It plays a crucial role in various cellular processes. The significance of ARD1 in tumor development has become increasingly evident in recent years.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This review analyzes the regulatory role of ARD1 in tumor progression by examining its involvement in processes such as cell cycle regulation, cell proliferation, metastasis, apoptosis, and autophagy. Additionally, we discuss the expression patterns and molecular mechanisms of ARD1 in different types of cancer.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Elevated levels of ARD1 have been reported in several cancer types. Its increased expression is associated with various tumor characteristics, suggesting it may serve as a potential prognostic biomarker. Furthermore, ARD1 could be targeted for the development of novel cancer therapies.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Understanding the role of ARD1 in tumor biology provides valuable insights into potential therapeutic targets and biomarkers for cancer treatment. This review highlights the advances in ARD1-related research and suggests that it may be a promising avenue for improving cancer prognosis and treatment strategies.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 5","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70708","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70708","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Arrest-deficient protein 1 (ARD1) is an acetyltransferase that acetylates the N-terminal amino acids and internal lysine residues of proteins. It plays a crucial role in various cellular processes. The significance of ARD1 in tumor development has become increasingly evident in recent years.

Methods

This review analyzes the regulatory role of ARD1 in tumor progression by examining its involvement in processes such as cell cycle regulation, cell proliferation, metastasis, apoptosis, and autophagy. Additionally, we discuss the expression patterns and molecular mechanisms of ARD1 in different types of cancer.

Results

Elevated levels of ARD1 have been reported in several cancer types. Its increased expression is associated with various tumor characteristics, suggesting it may serve as a potential prognostic biomarker. Furthermore, ARD1 could be targeted for the development of novel cancer therapies.

Conclusion

Understanding the role of ARD1 in tumor biology provides valuable insights into potential therapeutic targets and biomarkers for cancer treatment. This review highlights the advances in ARD1-related research and suggests that it may be a promising avenue for improving cancer prognosis and treatment strategies.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.